EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial



Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial



Hepatology 31(3): 730-736



Patients with chronic hepatitis C and low serum and hepatic iron stores may have an improved response to interferon (IFN). We tested whether iron reduction before and during IFN therapy would lead to an improved sustained biochemical and virological response compared with IFN alone. Eighty-two previously untreated patients with chronic hepatitis C were randomized to either: group A IFN-alpha2b 3 MU 3 times per week for 6 months, or group B iron reduction before and during IFN-alpha2b 3 MU 3 times per week for 6 months. Group B patients had lower mean serum alanine transaminase (ALT) levels than group A patients during treatment and follow-up. Group B patients had significantly lower mean hepatitis C virus (HCV)-RNA levels at treatment weeks 4 and 12 (P <.05). Serum HCV RNA was undetectable at the end of treatment in 15 group B patients compared with 7 group A patients (P =.03); 7 group B patients and 3 group A patients had persistently undetectable serum HCV RNA 24 weeks after the end of therapy (P =.20). Paired pre- and posttreatment liver biopsies in 18 group B patients demonstrated significant improvements in 2 of the 3 inflammation scores of the Knodell histological activity index (P <. 05). No changes occurred in the paired biopsies from 15 group A patients. We conclude that iron reduction via therapeutic phlebotomy improves the end-of-treatment virological and histological response to short-term IFN therapy. Additional studies are needed to determine if iron reduction in combination with higher doses or longer duration of IFN may be of benefit.

(PDF emailed within 0-6 h: $19.90)

Accession: 010885318

Download citation: RISBibTeXText

PMID: 10706565

DOI: 10.1002/hep.510310325



Related references

Iron reduction prior to and during interferon therapy of chronic hepatitis C Initial results of a multicenter, randomized, controlled trial in previously untreated patients. Gastroenterology 116(4 PART 2): A1191, April, 1999

Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial. Hepatology 32(1): 135-138, 2000

Iron depletion and interferon therapy A multicenter, randomized controlled trial in untreated non-cirrhotic patients with chronic hepatitis C. Hepatology 30(4 PART 2): 371A, 1999

A significant reduction in serum alanine aminotransferase levels after 3-month iron reduction therapy for chronic hepatitis C: a multicenter, prospective, randomized, controlled trial in Japan. Journal of Gastroenterology 39(6): 570-574, 2004

Iron reduction and sustained response to interferon-alpha therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study. American Journal of Gastroenterology 97(5): 1204-1210, 2002

Retreatment for chronic Hepatitis C of interferon non-responder patients Preliminary results of a multicenter randomized controlled trial of interferon plus ribavirin versus interferon alone. Hepatology 28(4 PART 2): 374A, 1998

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. New England Journal of Medicine 321(22): 1501-1506, 1989

Iron depletion and interferon therapy A multicenter, randomized trial in naive patients with chronic hepatitis C. Journal of Hepatology 32(Supplement 2): 114, 2000

Interferon-alfa plus indomethacin combination therapy in chronic hepatitis B A multicenter, randomized and controlled trial. Hepatology 30(4 PART 2): 644A, 1999

Low-dose alpha-interferon therapy can be effective in chronic active hepatitis C Results of a multicenter randomized trial. Gastroenterology 108(4 SUPPL ): A1162, 1995

Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial. Hepatology 21(2): 291-297, 1995

Daily induction treatment with alpha2b interferon in naive chronic hepatitis C patients results in a higher early response A controlled multicenter randomized trial. Hepatology 30(4 PART 2): 631A, 1999

Daily induction treatment with alfa2b interferon in naive chronic hepatitis C patients results in a higher early response, a controlled multicenter randomized trial. Gastroenterology 118(4 Suppl 2 Part 2): AASLD A149, April, 2000

Thymosin alpha-1 + interferon combination therapy for chronic hepatitis C Results of a randomized controlled trial. Hepatology 24(4 PART 2): 402A, 1996

Low doses of ribavirin are superior to high doses with interferon for chronic hepatitis C Results of a controlled, randomized, multicenter trial. Hepatology 30(4 PART 2): 265A, 1999